Related Experiment Video
Updated: Jun 10, 2026
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
[Acromegaly treatment with octreotide LAR in 42 cases]
Graciela Gómez-Martínez1, Ignacio Alejandro Martínez-Delgado
1Servicio de Endocrinología, Hospital de Especialidades 25, Centro Médico Nacional Noreste, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León, Mexico. graciela_gomez_mtz@hotmail.com
Objective:
To evaluate the efficacy of octreotide (OCT) LAR in patients with acromegaly.
Methods:
Observational, retrospective, transversal and descriptive study was done. Forty two patients with acromegaly (recently diagnosed and who have undergone surgery but not cured) followed up for 24 weeks were studied. There were 14 males (30 %) and 28 females (70 %) with an average age of 44 (range: 18-67 years). Dose adjustments of 10, 20 and 30 mg were made.
Results:
OCT LAR was administered in 24 patients who had been operated without cure and in 18 newly diagnosed patients. At 24 weeks of treatment in those patients not operated, GHm decreased 56 % and IGF-1 decreased 30 %. In patients who were operated but not cured, GHm decreased 49 % and IGF-1 decreased 53 %. For microadenomas, GHm decreased 57.6 % and IGF-1 60 %. For macroadenomas, decrease was 50 % and 37 %, respectively. The efficacy of OCT LAR on microadenomas, success was achieved (total and partial) in 65 % of patients and in 28 % of patients with macroadenomas.
Conclusions:
Patients with microadenomas and with lesser hypersomatotropinemia have a better response to treatment.
